Ultrasensitive bioluminescence immunoassays for the determination of peptides and proteins (illustrated with human urinary kallikrein, bradykinin and the determination of human urinary kallikrein antibody titers) have been developed. The usable ranges of the Standard curves are from 5 pg to 5000 pg per liter. The relative intra-assay coefficients of Variation of the tests were between 2 and 6%, and the interassay coefficients of Variation between 4 and 12%.
Introduction
Despite widespread application of radioimmunoassays, non-isotopic immunoassays have been developed during the past decade (l, 2). In particular, enzyme immunoassays (3 -8) have proved to be a useful alternative to radioimmunoassays. Although both radio-and enzyme immunoassays have similar sensitivities for antigen determination, enzyme immunoassay häs several advantages (9) and allows measurement of the signal in generally available spectrophotometers.
More recently, highly sensitive bipluminescent and luminescent detection Systems have become available for the determination of ATP and many different analytes (10) (11) (12) (13) . Bioluminescence is a natufal phen omenon found in many lower forms of life (14) . Naturally ocurring bioluminescent Systems differ with regard to the structure and function of enzymes and cofactors, äs well äs in the mechanism of the light emitting reactions (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) .
In this communication we describe and demonstrate highly sensitive enzyme immunoassays in which bio luminescence is used äs the detection System. The I.:tbisj. 25, 23-30(1987) .
principle of these bioluminescence enhanced immunoassays is äs follows: an antibody enzyme or antigen enzyme conjugate becomes bound in the enzyme immunoassay, then enzymatically releases ZMuciferin from luciferin derivatives. The D-luciferin is quantified in a luminometric assay.
Materials aiid Methods
Sephadex G-15, G-150 and N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP®) were products of Pharmacia Fine Chemicals, Uppsala, Sweden.
D-luciferin (Photinus pyralis)
, carboxylic esterase, carboxypeptidases A and B, arylsulphatase, alkaline phosphatase, Tween 20, and bovine semm albumin were purchased from Sigma Chemicals, Deisenhofen, FRG.
Glutardialdehyde was purchased from E. Merck, Darmstadt, FRG. Luciferase (Photinus pyralis; specific activity 8 mU/mg) was a product of Boehringer, Mannheim, FRG.
Bradykinin was a product of Novabiochem AG, Läufelfingen, Switzerland. Human urinary kallikrein was isolated äs described by Geiger et al. (22) . Antibodies against human urinary kallikrein and bradykinin were raised in rabbits and in goats äs already described (23) . IgG fractions were isolated according to Steinbuch & Audran (25) .
Bradykinin antibodies, purified by immunoaffmity, were prepared s described in 1. c. (26) .
Goat anti-rabbit immunoglobulins, purified by immunoaffinity, were purchased from M es/Yeda Ltd., Rehovot, Israel.
Microtiter plates were purchased from Dynatech, Denkendorf, FRG. D-luciferin methyl ester, ZMuciferyl-L-phenylalanine, ZMuciferyl-L-N a -arginine, ZMuciferin-O-sulphate and ZMuciferin-Ophosphate were synthesized s described (9).
Enzyme
2 ) conjugates Bradykinin, human urinary kallikrein and immunoglobulin G were conjugated with carboxylic esterase, carboxypeptidases A and B, arylsuiphatase and alkaline phosphatase. Coupling to carboxylic esterase was performed with glutardialdehyde and/ or N-succinimidyl 3-(2-pyridyldithio) proprionate (27) , and to carboxypeptidases A and B, arylsuiphatase and alkaline phosphatase with SPDP® s described by Carhson et al. (28) . All conjugates synthesized were purified by gel filtration on Sephadex G-15 (bradykinin) or G-150 (human urinary kallikrein and IgG) equilibrated with 0.1 mol/1 phosphate buffer, pH 7.5, containing 0.25 mol/1 NaCl, at 4°C. The concentrations of enzyme conjugates in the resulting reagent Solutions were determined by measuring enzyme activities by conventional methpds s described (9) . Aliquots of the enzyme conjugates were stored at -30 °C until use.
Luminometric assay
Luciferase activity was measured in a luminometer (Biolumat, Fa. Berthold Typ 9500 T, Wildbad, FRG) s follows (10): 0.4 ml incubation buffer (30 mmol/1 HEPES, 6.6 mmol/1 MgCl 2 , 0.66 mmol/1 EDTA, 0.1 mmol/1 dithiothreitol, 5 mmol/1 ATP, pH 7.75 containing l μg luciferase) was preincubated in a cuvette at 25 °C for 5 min in the luminometer. Thereafter 0.1 ml luciferin solution or incubation Solutions of the immunoassay were added and the integrated light impulses were monitored for 10 s.
Kinetics of luciferin liberation from luciferin derivatives
Microtiter plates were coated with rabbit IgG (10 mg/1 buffer A) overnight at 4 °C. After washing with buffer B (5 times), 0.2 ml of goat anti-rabbit IgG enzyme conjugates were added (for concentrations of enzyme conjugate in test, see table 1) and incubated at 37 °C for 5 h. Then the plates were washed with buffer B (5 times), 0.2 ml Substrate solution was added and luciferin release was measured after the time indicated. based detection Systems were incubated only for 30 min at 37 °C). Thereafter, 0.1 ml of the incubation mixture was transf ered to the luminometer and light impulses were monitored for 10 s. 
Competitive human urinary kallikrein enzyme immunoassay
Microtiter plates were coated with rabbit anti-human urinary kallikrein IgG (10 mg/1) in buffer A; 0.2 ml) at 4 °C overnight. Thereafter the plates were washed (5 times) with buffer B. Then 0.15 ml of human urinary kallikrein Standard or lest sample and 0.05 ml of a human urinary kallikrein enzyme conjugate solution (see above) were added, and the mixture was incubated for 24 h at 4 °C. The plates were washed with buffer B, then 0.2 ml of the corresponding D-luciferin derivative solution was added and detected äs described in "detection Systems".
Human urinary kallikrein immune enzymometric assay
Microtiter plates were coated with human urinary kallikrein (10 mg/1 buffer A; 0.2 ml per well) overnight at 4 °C. In parallel to, but separately from the coating procedure, 0.5 ml antihuman urinary källikrein IgG solution (0.1 g/l specific antibodies in buffer C) and 0.5 ml human urinary kallikrein solution (0.01 -10 ng/1 buffer C) were incubated in capped polypropylene vials overnight at 4 °C. The microtiter plates were washed with buffer B (5 times). Thereafter, 0.2 ml of each incubation mixture was transferred from the polypropylene vials to the corresponding microtiter plate wells and incubated at 37 °C for 5 h. After washing the plates (5 times), 0.2 ml of a goat anti-rabbit IgG enzyme conjugate solution in buffer C was added to each well and the plates were incubated again for 24h at 4°C. The plates were washed with buffer B (5 times), then the corresponding /Muciferin derivative solution (0.2 ml) was added to the wells. Bound IgG conjugates were detected äs described in Materials and Methods.
Human urinary kallikrein Sandwich antigen assay
Microtiter plates were coated with goat anti-human urinary kallikrein-IgG (10 mg/1 buffer A; 0.2 ml per well) at 4°C overnight. The plates were then washed (5 times) in buffer B.
Human urinary kallikrein Standard samples and test samples were diluted with buffer C. Of these samples 0.2 ml was added to the wells and the plates were incubated at 4 °C for 24 h. After incubation, the plates were washed (5 times) with buffer B, 0.2 ml of rabbit anti-human urinary kallikrein-IgG enzyme conjugate solution was added to each well, the plates were washed (5 times), then 0.2 ml of the corresponding ZMuciferin derivative Substrate solution (see detection Systems) was added to the wells, and the human urinary kallikrein-bound IgG conjugates were detected äs described in Materials and Methods.
Competitive bradykinin enzyme immunoassay
Microtiter plates were coated overnight at 4 °C with immunoselected anti-bradykinin IgG solution (10 mg/1 in buffer A; 0.2 ml per well). The plates were then washed with buffer B (5 times). Thereafter 0.15 ml bradykinin Standard solution in buffer C and 0.05 ml bradykinin enzyme conjugate were added to the wells and incubated at 4 °C for 24 h. Then the plates were washed with buffer B (5 times), the corresponding Dluciferin derivative solution was added (0.2 ml) to the wells, and the bound bradykinin conjugates were measured äs described in Materials and Methods. 
Enzyme immunoassay for titer determination
Microtiter plates were coated with antigen (10 mg/1 human urinary kallikrein in bufler A; 0.2 mi) at 4 °C overnight. The plates were then washed with buffer B (5 times). Thereafter 0.2 ml of difierent antiserum dilutions (10-0.001 μΐ anti-human urinary kallikrein serum in 0.2 ml buffer C) were added and incubated for 3 h at 37 °C. The plates were -washed -(5-times with buffer B), 0.2 ml of goat anti-rabbit IgG enzyme conjugate were added and incubated for 2 h at 37 °C, and the plates again washed with buffer B' (5 times). The corresponding /Muciferin derivative solution (0.2 ml) was added to the wells and the bound conjugates were measured s described in Materials and Methods.
Results and Discussion
Bradykinin, human urinary kallikrein and imrmmoglobulin G were conjugated to carboxylic esterase, carboxypeptidases A and B, arylsulphatase and alkaline phosphatase, according to established methods s described in Materials and Methods (27, 28) . The enzymatic activities of the conjugates after synthesis were sufficiently high for their intended use (tab. 1).
Using these enzyme conjugates, a number of different variants of immunoassays with different detection Systems were developed for the assay of bradykinin, human urinary kallikrein and for human urinary kallikrein antibody-titer determinations. The principles of the assays are shown schematically in figure 1. The bradykinin assay was perforrned s a cpinpetitive test ( fig. Id) , whereas f r human urinary kallikrein a competitive ( fig. l a) , an iiiamuno enzyinometric assay ( fig. l b) , and a sandwich antigen ass ^ ( fig. l c) were established. Anti human urinary kallikrein titers were measured by sandwich a tibody assay ( fig. l e) . The assays were performed s described in Materials and Methods.
Assay Systems were optimized with respect to enzyme immunoassay conditions (binding of antigen/aritibody to microtiter plates, antibody-antigen binding, etc.) s previ usly described (29) , and to optimal detection System conditions (concentration of substrates, temperatures, etc.). Luciferin liberation at 25 °C and 37 °C ( fig. 2 ), s well s the kinetics of the releasing reaction, was also investigated ( fig. 2 ). At 37 °C luciferin was liberated at a higher rate. Optimal Substrate concentrations for the detection Systems were determined by adding increasing amounts of/)-luciferin derivatives to the respective assay ( fig. 3 ). As can be seen from the data, optimal Substrate concentrations are in the r nge of about 10 μπιοΐ/ΐ. Incubation temperature: * = 37 P C,* ** == 25 °C.
• i
In figures 4 to 8 binding curves of different types of bioluminscence enhanced enzyme immunoassays for human urinary kallikrein, bradykinin and antibody titers (anti-human urinary kallikrein serum) are shown, using different detection Systems. The Standard curves were constructed by plotting the fraction of light impulses of the blank and the samples against the dose of antigens either in a logit-log mode (figs. 5 and 8) or in a linear-log mode (figs. 4, 6 and 7). The sensitivity and the slope of the curves vary, depending on the detection system and the type of enzyme.immunoassay. The sensitivities of the bioluminescence enhanced enzyme immunoassays were defined according to the method described by Kaiser (30) . The lowest concentration of human urinary kallikrein that produces a response greater than that caused in the absence of human urinary kallikrein was l fg per well in the immuno enzymometric assay ( fig. 7 ), corresponding to 5 pg/1. For bradykinin the lowest detectable concentration was l fg per well, corresponding to 5 pg/1 ( fig. 4) . The mass of antibodies necessary for 50% binding in the assay was 200 fg per well, corresponding to l ng/1 specific antihuman urinary kallikrein immunoglobulin G.
The determination of precision (intra-and inter-ssay coefficient of Variation), specificity and recovery of the assays led to the same results s previously published for enzyme immunoassays with peroxidase s label (26, 29) . The relative intra-assay coefficient of Variation (N between 15 and 25 for each assay; measured on different days) ranged from 2 to 6% for all assays and detection Systems. The intra-assay coefficient of Variation was calculated for all Standard curve concentrations (e. g. fig. 4 ; r nge 10~1 5 to 10" employing various bioluminescence detection Systems for different types of enzyme immunoassay. Depending on the enzyme conjugates and Substrates used, turnover rates of enzymes ranged from a kcat value of 11 s" 1 (carboxylic esterase (9)) up to 1010 s" 1 (alkaline phosphatase (9)). In figure 4 , dose response curves obtained for detection System f l to V in the competitive bradykinin bioluminescence enzyme immunoassay are shown. As cati be seen, alkaline phosphatase conjugates gave a response curve with the lowest detection limit. Titer detenninati ns (flg. 5) and the different types of human urinary kallikrein immunoassays (figs. 7, 8) showed simil f good results. Alkaline phosphatase conjugates gave the best reŝ ponses with the lowest limits of detection when compared with the other detection Systems.
The bioluminescence enhanced enzyme irnmunoassays described are useful for determination of antigens in a very low concentfation r nge (down to For assay conditions see Methods. · simple to perform, and the Substrates are stable at -20 °C in the dark for more than one year. Substrate Solutions can also be stored at -30 °C for some weeks.
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